Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EN2 divergent transcript (EN2-DT)
- Target
- EN2-DT
- Molecular classification
- Long noncoding RNA (lncRNA), Other (not a receptor, enzyme, transporter, or transcription factor)
01
Overview
EN2-DT is a noncoding RNA transcribed in the opposite direction to EN2 from a shared promoter region. Divergent transcription is a widespread phenomenon where noncoding RNAs and mRNAs are produced from opposite sides of a single promoter, and most divergent transcripts are unstable and rapidly degraded[1][3][4]. The steady-state level of the EN2-DT transcript, like most divergent transcripts, is typically low, and there is no current evidence that EN2-DT acts as a biomarker, therapeutic target, or has a defined role in disease[5]. In summary, EN2-DT refers to a noncoding RNA, not a receptor, enzyme, or therapeutic target, with poorly characterized biological functions and no established drug interactions or clinical utility.
- Other names
- EN2-DTEN2 divergent transcript
02
Mechanism of action
not applicable
03
Biological functions
May regulate expression of the adjacent protein-coding gene EN2 via transcriptional interference or chromatin modification, which is a generic function described for divergent lncRNAsOther potential regulatory roles (inferred from lncRNA biology)
04
Disease associations
not established; no direct link to cancer, inflammation, or other diseases is currently described for EN2-DT
Beyond the preview
Go deeper on EN2 divergent transcript (EN2-DT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EN2 divergent transcript (EN2-DT).